You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

28 Results
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma
New Drug Funding Program
    Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gilteritinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
vemURAFenib (Unfunded),
riTUXimab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022

Pages